AR075366A1 - Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa - Google Patents

Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa

Info

Publication number
AR075366A1
AR075366A1 ARP100100325A ARP100100325A AR075366A1 AR 075366 A1 AR075366 A1 AR 075366A1 AR P100100325 A ARP100100325 A AR P100100325A AR P100100325 A ARP100100325 A AR P100100325A AR 075366 A1 AR075366 A1 AR 075366A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
substituents
optionally substituted
cycloalkyl
Prior art date
Application number
ARP100100325A
Other languages
English (en)
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of AR075366A1 publication Critical patent/AR075366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos segun la presente resultan de utilidad como moduladores de la gamma secreta. También se refiere a los procedimientos para elaborar tales compuestos, a composiciones farmacéuticas que comprenden dichos compuestos a modo de ingrediente activo, así como al uso de dichos compuestos como medicamento. Reivindicacion 1: Un compuesto de la formula (1) o una forma estereoisomérica de éste, donde Het1 es un heterociclo aromático de 5 o 6 miembros que tiene la formula (2), (3), (4), (5) o (6); R0 es H o alquilo C1-4; R1 es H, alquilo C1-4 o alquil C1-4-oxialquilo C1-4; R2 es alquilo C1-4; X es O o S; G1 es CH o N; G2 es CH, N o C sustituido con alquilo C1-4; siempre que G1 y G2 no sean simultáneamente N; G3 es CH o N; R10a y R10b son, cada uno de manera independiente, hidrogeno o alquilo C1-4; A1 es CR3 o N; donde R3 es H, halo o alquil C1-4oxi; cada uno de A2, A3 y A4 es, de manera independiente, CH, CF o N; siempre que un máximo de dos de A1, A2, A3 y A4 sean N; Het2 es un heterociclo aromático bicíclico de 9 miembros que tiene la formula (7) o (8); Z1 es CH o N; Z2 es CR4a o N; Z3 es CH o N; siempre que como máximo uno de Z1, Z2 y Z3 sea N; Y1 es CH o N; Y2 es CR4b o N; Y3 es CH o N; siempre que como máximo uno de Y1, Y2 e Y3 sea N; R4a es H; halo; alquil C1-4oxi; ciano; cicloalquilo C3-7; alquil C1-4carbonilo; alquil C1-4oxicarbonilo o alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo y amino; R4b es H; halo; alquil C1-4oxi; ciano; cicloalquilo C3-7 o alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo y amino; R5 es H; halo; ciano; alquil C1-4oxi; alquenilo C2-6 o alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en alquil C1-4oxi y halo; R6a es alquilo C2-6 sustituido con uno o más sustituyentes de halo; alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en piperidinilo, Ar, alquil C1-6oxi, tetrahidropiranilo, cicloalquil C3-7oxi y cicloalquilo C3-7; cicloalquilo C3-7; alquil C1-4carbonilo; tetrahidropiranilo; Ar; R8R9N-carbonilo o CH2-O-Ar; R6b es alquilo C2-6 sustituido con uno o más sustituyentes de halo; alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en piperidinilo, Ar, alquil C1-6oxi, tetrahidropiranilo, cicloalquil C3-7oxi y cicloalquilo C3-7; cicloalquilo C3-7; cicloalquilo C3-7 sustituido con uno o más sustituyentes de fenilo opcionalmente sustituido con uno o más sustituyentes de halo; piperidinilo; morfolinilo; pirrolidinilo; NR8R9 tetrahidropiranilo; O-Ar; alquil C1-6oxi; alquil C1-6tio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar o NH-Ar; donde cada piperidinilo, morfolinilo y pirrolidinilo puede estar opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en alquilo C1-4, alquenilo C2-6, alquil C1-4carbonílo, halo, y alquil C1-4oxicarbonilo; donde cada Ar es, de manera independiente, fenilo opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo, alquil C1-4oxi, ciano, NR8R9, morfolinilo, alquilo C1-4 y alquilo C1-4 sustituido con uno o más sustituyentes de halo; piridinilo opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo, alquil C1-4oxi, ciano, alquilo C1-4 y alquilo C1-4 sustituido con uno o más sustituyentes de halo; oxazolilo opcionalmente sustituido con uno o más sustituyentes de alquilo C1-4; o tienilo opcionalmente sustituido con uno o más sustituyentes de halo; cada R8 es, de manera independiente, H o alquilo C1-4; cada R9 es, de manera independiente, H o alquilo C1-4; R7 es H, alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo, fenilo, y alquil C1-4oxi; o una sal de adicion farmacéuticamente aceptable o solvato de aquél.
ARP100100325A 2009-02-06 2010-02-05 Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa AR075366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09152254 2009-02-06

Publications (1)

Publication Number Publication Date
AR075366A1 true AR075366A1 (es) 2011-03-30

Family

ID=40756688

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100325A AR075366A1 (es) 2009-02-06 2010-02-05 Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa

Country Status (20)

Country Link
US (2) US8946426B2 (es)
EP (1) EP2393804B1 (es)
JP (1) JP5576403B2 (es)
KR (1) KR20110113197A (es)
CN (1) CN102325765B (es)
AP (1) AP2011005779A0 (es)
AR (1) AR075366A1 (es)
AU (1) AU2010211109B2 (es)
BR (1) BRPI1008473A2 (es)
CA (1) CA2748862A1 (es)
EA (1) EA019685B1 (es)
ES (1) ES2481715T3 (es)
IL (1) IL214425A (es)
MX (1) MX2011008335A (es)
NZ (1) NZ593951A (es)
SG (1) SG173510A1 (es)
TW (1) TWI496780B (es)
UA (1) UA106360C2 (es)
WO (1) WO2010089292A1 (es)
ZA (1) ZA201105788B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2539568C2 (ru) 2008-10-31 2015-01-20 Дженентек, Инк. Пиразолопиримидиновые соединения-ингибиторы jak и способы
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
EP2427453B1 (en) 2009-05-07 2013-07-17 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
EA021047B1 (ru) 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
PE20121511A1 (es) 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
US20130096104A1 (en) * 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
RU2013114352A (ru) 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
CA2817785A1 (en) 2010-11-19 2012-05-24 Toby Blench Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы
EP2768833A4 (en) * 2011-10-20 2015-04-15 Sirtris Pharmaceuticals Inc SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS MODULATORS OF SIRTUINS
EP2768509B1 (en) 2011-10-20 2017-03-22 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
CN104136431B (zh) 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ，インコーポレーテッド （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
FR2993564B1 (fr) 2012-07-20 2014-08-22 Metabrain Res Derives d'imidazopyridine utiles dans le traitement du diabete
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
JP6052527B2 (ja) 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉ
WO2014127816A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
PE20211782A1 (es) 2014-05-23 2021-09-08 Hoffmann La Roche Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
JP6628805B2 (ja) 2015-02-03 2020-01-15 ファイザー・インク 新規シクロプロパベンゾフラニルピリドピラジンジオン
HRP20210508T1 (hr) 2016-06-16 2021-05-28 Janssen Pharmaceutica Nv Biciklički derivati piridina, pirazina i pirimidina kao inhibitori pi3k beta
EP3475279B1 (en) 2016-06-27 2021-07-14 F. Hoffmann-La Roche AG Triazolopyridines as gamma-secretase modulators
US10435411B2 (en) 2016-11-01 2019-10-08 Nihon Nohyaku Co., Ltd. Oxime group-containing quinoline compound, N-oxide thereof or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
RU2769696C2 (ru) 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
KR20260007293A (ko) * 2018-02-02 2026-01-13 제넨테크, 인크. 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
CN108440509B (zh) * 2018-04-23 2021-03-02 山西大同大学 一种阿托伐他汀钙中间体制备的方法
WO2023066299A1 (en) * 2021-10-19 2023-04-27 Impact Therapeutics (Shanghai) , Inc Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
EP0839144B1 (en) 1995-07-13 2001-09-19 Knoll GmbH Piperazine derivatives as therapeutic agents
CN1156445C (zh) 1999-06-10 2004-07-07 沃尼尔·朗伯公司 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
WO2001078721A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
CN1753891A (zh) 2003-02-27 2006-03-29 霍夫曼-拉罗奇有限公司 Ccr－3受体拮抗剂
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
MXPA06001660A (es) 2003-08-14 2006-04-28 Hoffmann La Roche Moduladores gabanergicos.
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
ZA200609845B (en) * 2004-05-26 2010-02-24 Eisai R&D Man Co Ltd Cinnamide compound
CA2566094A1 (en) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. Cinnamide compound
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2623317A1 (en) 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as ccr3 receptor liquids
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
WO2007044895A2 (en) 2005-10-11 2007-04-19 Chemtura Corporation Diaromatic amines
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US7951818B2 (en) 2006-12-01 2011-05-31 Galapagos Nv Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
CN101631779A (zh) 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
CA2677296A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme piperidine
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
WO2008137139A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
DE602008004769D1 (en) 2007-05-11 2011-03-10 Hoffmann La Roche Hetarylaniline als modulatoren für amyloid beta
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
WO2009005729A1 (en) 2007-06-29 2009-01-08 Schering Corporation Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
MX2010006243A (es) 2007-12-06 2010-08-31 Schering Corp Moduladores de gamma secretasa.
CA2708300A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010054067A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
EP2367817A4 (en) 2008-12-03 2012-05-09 Via Pharmaceuticals Inc INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
AU2010218714A1 (en) 2009-02-26 2011-09-08 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
CA2751534A1 (en) 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
WO2010106745A1 (ja) 2009-03-16 2010-09-23 パナソニック株式会社 アプリケーション実行装置
AU2010241929A1 (en) 2009-04-27 2011-10-06 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
EP2427453B1 (en) 2009-05-07 2013-07-17 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
EA021047B1 (ru) 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
PE20121511A1 (es) 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы

Also Published As

Publication number Publication date
JP5576403B2 (ja) 2014-08-20
IL214425A0 (en) 2011-09-27
NZ593951A (en) 2013-01-25
WO2010089292A1 (en) 2010-08-12
AP2011005779A0 (en) 2011-08-31
EA201171008A1 (ru) 2012-02-28
IL214425A (en) 2015-07-30
BRPI1008473A2 (pt) 2019-04-02
UA106360C2 (ru) 2014-08-26
CA2748862A1 (en) 2010-08-12
US20150094311A1 (en) 2015-04-02
AU2010211109A1 (en) 2011-07-21
EP2393804A1 (en) 2011-12-14
EA019685B1 (ru) 2014-05-30
AU2010211109B2 (en) 2014-11-27
CN102325765A (zh) 2012-01-18
ES2481715T3 (es) 2014-07-31
EP2393804B1 (en) 2014-04-16
MX2011008335A (es) 2011-09-06
ZA201105788B (en) 2015-06-24
JP2012516870A (ja) 2012-07-26
US8946426B2 (en) 2015-02-03
TW201040176A (en) 2010-11-16
US20110281881A1 (en) 2011-11-17
SG173510A1 (en) 2011-09-29
KR20110113197A (ko) 2011-10-14
TWI496780B (zh) 2015-08-21
CN102325765B (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
AR075366A1 (es) Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa
PH12020550552A1 (en) Inhibitors of hepatitis c virus
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR087182A1 (es) DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
PY1153144A (es) Inhibidores macrocíclicos de virus flaviviridae
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MX2014011829A (es) Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales.
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
MX354175B (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria.
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
MX2013011551A (es) Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales.
WO2015200677A3 (en) Prmt5 inhibitors and uses thereof
AR062526A1 (es) DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER.
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
AR079904A1 (es) Derivados de triazol sustituidos como moduladores de la gamma secretasa
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
MX2014011995A (es) Compuestos de furanona heterobicíclicos n-sustituidos y derivados para combatir plagas de animales.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal